Anna Gisselsson

Director/Miembro de la Junta en Moroxite F AB .

Finance

Consumer Services

Commercial Services

Perfil

Anna Gisselsson is currently working as a Director at Moroxite F AB and as an Investment Manager at Almi Invest AB.
She has a graduate and doctorate degree from the Faculty of Engineering, Lund University.

Cargos activos de Anna Gisselsson

Empresas	Cargo	Inicio
Almi Invest AB Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden.	Inversor de Capital Privado	01/11/2020
Moroxite F AB Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures.	Director/Miembro de la Junta	-

Todos los cargos activos de Anna Gisselsson

Formación de Anna Gisselsson.

Faculty of Engineering, Lund University

Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Anna Gisselsson.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
Almi Invest AB Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden.	Finance
Moroxite F AB Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures.	Commercial Services